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A BS TR AC T
BACKGROUND
Early enteral feeding through a nasoenteric feeding tube is often used in patients 
with severe acute pancreatitis to prevent gut-derived infections, but evidence to sup-
port this strategy is limited. We conducted a multicenter, randomized trial compar-
ing early nasoenteric tube feeding with an oral diet at 72 hours after presentation 
to the emergency department in patients with acute pancreatitis.
METHODS
We enrolled patients with acute pancreatitis who were at high risk for complications 
on the basis of an Acute Physiology and Chronic Health Evaluation II score of 8 or 
higher (on a scale of 0 to 71, with higher scores indicating more severe disease), an 
Imrie or modified Glasgow score of 3 or higher (on a scale of 0 to 8, with higher 
scores indicating more severe disease), or a serum C-reactive protein level of more 
than 150 mg per liter. Patients were randomly assigned to nasoenteric tube feeding 
within 24 hours after randomization (early group) or to an oral diet initiated 72 hours 
after presentation (on-demand group), with tube feeding provided if the oral diet was 
not tolerated. The primary end point was a composite of major infection (infected 
pancreatic necrosis, bacteremia, or pneumonia) or death during 6 months of follow-up.
RESULTS
A total of 208 patients were enrolled at 19 Dutch hospitals. The primary end point 
occurred in 30 of 101 patients (30%) in the early group and in 28 of 104 (27%) in 
the on-demand group (risk ratio, 1.07; 95% confidence interval, 0.79 to 1.44; 
P = 0.76). There were no significant differences between the early group and the on-
demand group in the rate of major infection (25% and 26%, respectively; P = 0.87) 
or death (11% and 7%, respectively; P = 0.33). In the on-demand group, 72 patients 
(69%) tolerated an oral diet and did not require tube feeding.
CONCLUSIONS
This trial did not show the superiority of early nasoenteric tube feeding, as com-
pared with an oral diet after 72 hours, in reducing the rate of infection or death 
in patients with acute pancreatitis at high risk for complications. (Funded by the 
Netherlands Organization for Health Research and Development and others; 
 PYTHON Current Controlled Trials number, ISRCTN18170985.)
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A cute pancreatitis is the most com-mon gastrointestinal disease leading to hospital admission, and its incidence con-
tinues to rise.1-4 Most patients with acute pancre-
atitis recover uneventfully and are discharged 
after a few days.5,6 In 20% of patients, the dis-
ease course is complicated by major infection, 
such as infected pancreatic necrosis, which is 
associated with a mortality of 15%.7-11
A meta-analysis of eight randomized trials 
involving 348 patients showed that nasoenteric 
tube feeding, as compared with total parenteral 
nutrition, reduced the rate of infections and 
mortality among patients with severe pancreati-
tis.12 These infections are thought to be medi-
ated by bacterial translocation from the gut, 
provoked by disturbed intestinal motility, bacte-
rial overgrowth, and increased mucosal perme-
ability.13-18 Nasoenteric tube feeding is believed 
to stimulate intestinal motility — thus reducing 
bacterial overgrowth — and may increase 
splanchnic blood flow, which helps to preserve 
the integrity of the gut mucosa.19,20 Total paren-
teral nutrition lacks the trophic effect of enteric 
feeding and is associated with central venous 
catheter–related infections as well as metabolic 
complications.21
A meta-analysis of randomized trials involv-
ing acutely ill patients admitted to the hospital 
for indications other than pancreatitis showed a 
22% reduction in the rate of major infection 
when nasoenteric tube feeding was started very 
early (≤36 hours after admission or surgery) as 
compared with a later start.22 Similarly, nonran-
domized studies of acute pancreatitis have shown 
that nasoenteric tube feeding started within 48 
hours after admission, as compared with a start 
after 48 hours, significantly reduced the rate of 
major infection and in some studies even re-
duced mortality.23-26
On the basis of these potential benefits, 
American and European nutritional societies 
recommend routine early nasoenteric tube feed-
ing in all patients with severe pancreatitis.27-29 
Guidelines from gastroenterologic and pancreatic 
societies, however, state that, regardless of dis-
ease severity, tube feeding is indicated when 
patients are not able to tolerate an oral diet for up 
to 7 days.30,31 Unfortunately, it takes 3 to 4 days 
after admission to make this assessment,32 and 
by that time the window of opportunity for effec-
tive prevention of infection with early tube feed-
ing has passed.7 To address this problem in the 
management of acute pancreatitis, we compared 
the effects of early nasoenteric tube feeding with 
those of an oral diet started at 72 hours, with a 
switch to nasoenteric tube feeding only in the 
case of insufficient oral intake.
ME THODS
STUDY PARTICIPANTS
The protocol of the Pancreatitis, Very Early Com-
pared with Selective Delayed Start of Enteral 
Feeding (PYTHON) trial has been published pre-
viously33 and is available with the full text of this 
article at NEJM.org. The study was conducted ac-
cording to the protocol. Adults with a first epi-
sode of acute pancreatitis who were at high risk 
for complications (i.e., patients predicted to have 
severe pancreatitis) were eligible to undergo ran-
domization. Patients were considered to be at 
high risk for complications if, within 24 hours 
after presentation to the emergency department, 
the Acute Physiology and Chronic Health Evalua-
tion (APACHE) II34 score was 8 or higher (on a 
scale of 0 to 71, with higher scores indicating 
more severe disease), if the Imrie or modified 
Glasgow score35 was 3 or higher (on a scale of 
0 to 8, with higher scores indicating more severe 
disease), or if the serum C-reactive protein level 
was more than 150 mg per liter.36 These assess-
ments predict the development of complications 
during the course of the disease. Pancreatitis was 
diagnosed if at least two of the three following 
features were present: typical abdominal pain, a 
serum lipase or amylase level that was more than 
3 times the upper limit of the normal range, or 
characteristic findings on cross-sectional imag-
ing of the abdomen. The exclusion criteria are 
given in the Supplementary Appendix, available 
at NEJM.org.
STUDY DESIGN AND OVERSIGHT
The PYTHON trial was a multicenter, random-
ized, controlled superiority trial performed in six 
university medical centers and 13 large teaching 
hospitals of the Dutch Pancreatitis Study Group. 
Patients were randomly assigned in a 1:1 ratio 
either to nasoenteric tube feeding initiated with-
in 24 hours after randomization (the early group) 
or to an oral diet starting at 72 hours (the on-
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demand group). Randomization was performed 
centrally by the study coordinator with the use of 
a Web-based system that used permuted-block 
randomization with a concealed, varying block 
size. Randomization was stratified according to 
treatment center and a dichotomized APACHE II 
score (<13 vs. ≥13); the latter stratification factor 
was used because patients with an APACHE II 
score of 13 or higher are at increased risk for 
major infection.
All the patients or their legal representatives 
provided written informed consent. The study 
protocol was approved by the institutional review 
board of the University Medical Center Utrecht 
and by all the participating centers. All the au-
thors vouch for the veracity and completeness of 
the data and data analyses. The sponsors were 
not involved in the design or conduct of the 
study or in the preparation of the manuscript or 
the decision to submit it for publication.
STUDY PROCEDURES
Patients underwent randomization within 24 hours 
after presentation to the emergency department. 
Those assigned to early nasoenteric feeding re-
ceived a nasojejunal feeding tube as soon as pos-
sible but not later than 24 hours after randomiza-
tion. Feeding tubes were placed endoscopically 
or radiologically, according to local practice. Naso-
enteric feeding was administered as Nutrison 
Protein Plus (Nutricia). After tube placement, 
feeding was started at 20 ml per hour during the 
first 24 hours and was gradually increased (see 
the Supplementary Appendix). In the two study 
groups, full nutrition was defined as an energy 
target of 25 kcal per kilogram of body weight per 
day for patients in the intensive care unit (ICU) 
and 30 kcal per kilogram per day for patients in 
the ward.28,37,38
Patients assigned to an oral diet did not re-
ceive nutrition by any means other than that 
provided by standard intravenous f luids during 
the first 72 hours after presentation to the 
emergency department. Exceptions were made 
for patients who requested oral food during this 
72-hour period. At 72 hours, all the patients in 
the on-demand group were given an oral diet. 
If an oral diet was not tolerated, it was offered 
again after 24 hours. If an oral diet still was 
not tolerated after 96 hours from the time of 
presentation, nasoenteric feeding was started 
after the placement of a nasojejunal tube, and 
the same procedure was followed as in the early 
group.
END POINTS
The primary end point was a composite of major 
infection or death within 6 months after random-
ization. Major infection was defined as infected 
pancreatic necrosis, bacteremia, or pneumonia 
(for definitions, see Box S1 in the Supplementary 
Appendix). Predefined secondary end points in-
cluded the development of necrotizing pancreati-
tis as diagnosed on the basis of computed tomog-
raphy (CT) performed 5 to 7 days after admission 
(because pancreatic parenchymal necrosis may 
take up to 72 hours to develop) and the develop-
ment of organ failure after randomization.
DATA COLLECTION AND END-POINT ASSESSMENT
Dieticians registered the caloric intake and calcu-
lated energy-intake targets during the first week 
after admission on the basis of actual body 
weight. All CT studies were interpreted by an 
author who is an experienced radiologist and 
who was unaware of the treatment assignments. 
An adjudication committee, consisting of four 
pancreatic surgeons and a gastroenterologist who 
were unaware of the treatment assignments, in-
dividually evaluated each patient for the occur-
rence of the primary end point before interim 
and final analyses. Disagreements with respect 
to major infection were resolved during a plenary 
consensus meeting.
PATIENT SAFETY
An independent data and safety monitoring com-
mittee evaluated the progress of the trial and ex-
amined safety end points after the completion of 
follow-up in each consecutive group of 25 patients. 
Adverse events were listed and presented to the 
data and safety monitoring committee in an un-
blinded fashion.
STATISTICAL ANALYSIS
The expected incidence of the primary end point 
in the on-demand group was based on data from 
individual patients in the placebo group of a pre-
vious randomized trial.39 For the early group, 
data from randomized trials comparing nasoen-
teric with parenteral nutrition were used to esti-
mate the incidence.33,40-42 The sample-size calcu-
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lation was based on an expected reduction in the 
primary composite end point associated with 
early tube feeding from 40 to 22%.33 We esti-
mated that a sample of 208 patients would pro-
vide the study with at least 80% power, at a two-
sided alpha level of 5% and assuming a 1% loss 
to follow-up. Analysis was based on the inten-
tion-to-treat method, with the exclusion only of 
patients for whom the adjudication committee, 
whose members were unaware of the treatment 
assignments, decided before any analysis that the 
diagnosis of acute pancreatitis was incorrect.
Predefined subgroups included patients with 
an APACHE II score below 13 and those with a 
score of 13 or higher at randomization. Two post 
hoc subgroup analyses were performed: one for 
patients with the systemic inflammatory re-
sponse syndrome (SIRS, as defined by the Con-
sensus Conference criteria of the American Col-
lege of Chest Physicians–Society of Critical Care 
Medicine) at randomization, because such pa-
tients are at high risk for complications,43 and 
one for a low or high body-mass index (BMI; the 
weight in kilograms divided by the square of the 
height in meters), since the BMI differed sig-
nificantly between the two treatment groups at 
baseline.
An interim analysis of the primary end point 
was performed after 50% of the patients had 
completed 6 months of follow-up. The interim 
analysis was performed by an independent statis-
tician, who was unaware of the treatment assign-
ments, applying the Peto approach with symmet-
ric stopping boundaries at a P value of less than 
0.001.33,44
For the final analyses, a two-sided P value of 
less than 0.05 was considered to indicate statis-
tical significance. P values were not adjusted for 
multiple testing.
R ESULT S
ENROLLMENT AND RANDOMIZATION
From August 2008 through June 2012, a total of 
867 patients were assessed for eligibility (Fig. S1 in 
the Supplementary Appendix). A total of 208 pa-
tients (24%) were enrolled and randomly assigned 
to early nasoenteric tube feeding (102 patients) or 
an oral diet with tube feeding if required (106). 
The adjudication committee excluded 3 patients 
who had undergone randomization and had been 
incorrectly diagnosed with acute pancreatitis 
(2 patients had gastric carcinoma and 1 had in-
testinal volvulus). A total of 101 patients in the 
early group and 104 in the on-demand group 
were included in the intention-to-treat analysis. 
Baseline characteristics, presented in Table 1, 
were equally distributed between the groups ex-
cept for the mean (±SD) BMI (29±5 in the early 
group vs. 27±5 in the on-demand group, P = 0.01).
Details regarding the number of calories de-
livered during the first week after admission and 
the timing of feeding are shown in Figure 1, and 
in Table S1 in the Supplementary Appendix. As 
specified by the protocol, patients in the early 
group received feeding earlier than those in the 
on-demand group. Nasoenteric tube feeding in 
the early group was started a median of 8 hours 
after randomization and a median of 23 hours 
after presentation to the emergency department, 
as compared with initiation of an oral diet 64 
hours after randomization and 72 hours after 
presentation in the on-demand group (P<0.001) 
(Table S1 in the Supplementary Appendix). A 
total of 5 of 104 patients (5%) assigned to on-
demand feeding requested and received food 
within the first 72 hours after presentation.
OUTCOMES
Primary End Point
The primary composite end point of major infec-
tion or death occurred in 30 patients (30%) in the 
early group, as compared with 28 (27%) in the 
on-demand group (risk ratio, 1.07; 95% confi-
dence interval [CI], 0.79 to 1.44; absolute risk 
difference, 3 percentage points; 95% CI, −9 to 15; 
P = 0.76). Major infections occurred in 25% of the 
patients in the early group and in 26% of those in 
the on-demand group (P = 0.87) (Table 2). Mor-
tality was 11% in the early group, as compared 
with 7% in the on-demand group (P = 0.33), and 
most of the deaths were related to persistent 
multiple organ failure (defined as failure of two 
or more organs on ≥3 consecutive days).
Secondary End Points
Necrotizing pancreatitis developed in 63% of 
the patients in the early group and in 62% of 
those in the on-demand group. A total of 18% 
of the patients in the early group and 19% of 
those in the on-demand group required ICU ad-
mission (Table 2).
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Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Early
Tube Feeding
(N = 101)
On-Demand
Tube Feeding
(N = 104)
Female sex — no. (%) 46 (46) 45 (43)
Age — yr 65±16 65±15
Cause of pancreatitis — no. (%)
Gallstones 59 (58) 56 (54)
Alcohol abuse 14 (14) 23 (22)
Other 28 (28) 25 (24)
Body-mass index — no./total no. (%)†
<25 20/99 (20) 33/103 (32)
25 to <35 69/99 (70) 67/103 (65)
≥35 10/99 (10) 3/103 (3)
Disease severity
APACHE II score‡
Mean 11±4 11±5
≥13§ 32 (32) 29 (28)
Imrie or modified Glasgow score¶
Median 2 2
Range 0–6 0–5
C-reactive protein — mg/liter
Median 70 75
Interquartile range 21–179 11–189
SIRS — no. (%)‖ 63 (62) 70 (67)
Respiratory failure — no. (%) 30 (30) 27 (26)
Multiple organ failure — no. (%)** 6 (6) 5 (5)
Duration — hr
Onset of symptoms to presentation at the emergency 
department
Median 12 13
Interquartile range 5–28 4–33
Presentation at the emergency department  
to randomization
Median 13 11
Interquartile range 5–19 4–19
* Plus–minus values are means ±SD. There were no significant between-group differences at baseline, except for body-
mass index (P = 0.01).
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores 
 indicating more severe disease.34
§ Patients with an APACHE II score of 13 or higher constituted a predefined subgroup.
¶ Imrie or modified Glasgow35 scores range from 0 to 8, with higher scores indicating more severe disease.
‖ The systemic inflammatory response syndrome (SIRS) was diagnosed with the use of the Consensus Conference criteria 
of the American College of Chest Physicians–Society of Critical Care Medicine.
** Organ failure was defined as a modified Marshall score of 2 or more (on a scale of 0 to 12, with higher scores indicating 
more severe disease), as proposed in the revised Atlanta classification of acute pancreatitis.45 Multiple organ failure 
was defined as failure of two or more organs on the same day.
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In the on-demand group, 32 patients (31%) 
required nasoenteric tube feeding; 72 patients 
(69%) tolerated an oral diet and did not require 
tube feeding (Table 3). In 9 of these 32 patients 
(28%), tube feeding was prompted by the use of 
mechanical ventilation. The on-demand tube-
feeding strategy reduced the number of days to 
full tolerance of an oral diet (9 days with the 
early strategy vs. 6 days with the on-demand 
strategy, P = 0.001). Gastrointestinal events oc-
curred frequently, but the frequency did not dif-
fer significantly between the groups.
Attenuation of the acute inflammatory re-
sponse was hypothesized to be part of the ben-
eficial effect of early feeding. However, such an 
effect did not occur (Fig. S3 in the Supplemen-
tary Appendix).
In a predefined subgroup analysis restricted 
to patients with an APACHE II score of 13 or 
higher at randomization, the occurrence of the 
primary end point did not differ significantly 
between the two treatment groups (Table S3 in 
the Supplementary Appendix). Post hoc subgroup 
analyses also did not show a significant between-
group difference in the primary end point for 
patients with SIRS at randomization or those 
with a BMI of less than 25 or 35 or more (Table 
S3 in the Supplementary Appendix). No signifi-
cant differences were observed in health care 
utilization except for the number of tube place-
ments (145 tube placements in the early group 
vs. 57 in the on-demand group, P<0.001) (Table 
S4 in the Supplementary Appendix).
DISCUSSION
This multicenter, randomized trial involving pa-
tients with acute pancreatitis who were at high 
risk for complications did not show that an early 
start of nasoenteric tube feeding was superior to 
the introduction of an oral diet after 72 hours, 
with tube feeding only if required, in reducing 
the composite end point of major infection or 
death. With the oral diet and on-demand tube-
feeding strategy, only approximately one third of 
patients required a nasojejunal feeding tube.
The absolute between-group difference in the 
primary end point was 3 percentage points, with 
the 95% confidence interval ranging from 9 per-
centage points lower to 15 percentage points 
higher. These findings do not support clinical 
guidelines recommending the early start of naso-
enteric tube feeding in all patients with severe 
acute pancreatitis in order to reduce the risks of 
infection and death. However, this trial was not 
powered to exclude a substantial benefit of early 
feeding.
The results of our trial differ from those of 
previous trials and observational studies.12,23-26 
Previous trials showed an improved outcome 
after early nasoenteric tube feeding as compared 
with total parenteral nutrition. This may be ex-
plained in part by complications associated 
with providing total parenteral nutrition, such as 
catheter-related infections.21 The negative out-
come of our study, as compared with the out-
comes in these previous trials, is not explained 
by differences in the timing of early tube feeding 
or the severity of pancreatitis in the study par-
ticipants. The timing of early nasoenteric tube 
feeding in our study was similar to the timing 
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in the previous studies. In addition, we used 
similar criteria for enrolling patients at high risk 
for complications, and we observed similar rates 
of major infection and death.
Previous observational studies investigating 
the initiation of nasoenteric tube feeding within 
48 hours after admission, as compared with 
initiation more than 48 hours after admission, 
cannot differentiate between cause and effect 
(i.e., less severely ill patients may have been fed 
earlier). This is in line with a recently revived 
debate on the presumed benefit of early enteral 
feeding in critically ill patients in general. Early 
enteral feeding is recommended in most current 
ICU guidelines.38,47 However, the methodologic 
quality of the trials that form the basis for these 
general ICU recommendations has been criti-
cized.48 Thus, for critically ill patients in general 
and for those with acute pancreatitis specifical-
ly, large, high-quality, randomized, controlled 
trials that show an improved outcome with early 
enteral feeding are lacking.49
There are several possible explanations for 
the negative result of our study. First, early en-
teral feeding may not be as effective as we antici-
pated. Our hypothesis was that the trophic effect 
of early enteral feeding would stabilize the integ-
rity of the gut mucosa, reducing inflammation 
and improving the outcome. Early enteral feed-
ing was not associated with a reduction in any 
Table 2. Primary and Secondary End Points, According to the Intention-to-Treat Analysis.*
Outcome
Early  
Tube Feeding
(N = 101)
On-Demand  
Tube Feeding
(N = 104)
Risk Ratio
(95% CI) P Value
Primary composite end point: infection 
or death — no. (%)
30 (30) 28 (27) 1.07 (0.79–1.44) 0.76
Secondary end points
Infection — no. (%)† 25 (25) 27 (26) 0.97 (0.70–1.34) 0.87
Infected pancreatic necrosis 9 (9) 15 (14) 0.74 (0.43–1.26) 0.28
Bacteremia 17 (17) 18 (17) 0.98 (0.68–1.43) 1.00
Pneumonia 12 (12) 13 (12) 0.97 (0.63–1.50) 1.00
Death — no. (%) 11 (11) 7 (7) 1.27 (0.85–1.89) 0.33
Necrotizing pancreatitis — no. (%)‡ 64 (63) 65 (62) 1.06 (0.77–1.47) 0.76
CT severity index§ 4±2 4±3 — 0.29
ICU admission after randomization 
— no. (%)
18 (18) 20 (19) 0.95 (0.66–1.38) 0.86
Mechanical ventilation — no. (%) 12 (12) 14 (13) 0.93 (0.60–1.44) 0.84
New-onset organ failure — no./total 
no. at risk (%)¶
Single organ failure 26/67 (39) 31/73 (42) 0.92 (0.65–1.32) 0.73
Persistent single organ failure 10/67 (15) 10/73 (14) 1.05 (0.65–1.70) 1.00
Multiple organ failure  7/67 (10) 6/73 (8) 1.14 (0.67–1.95) 0.77
Persistent multiple organ failure 4/67 (6) 4/73 (5) 1.05 (0.51–2.14) 1.00
* Plus-minus values are means ±SD. Risk ratios are for early tube feeding as compared with on-demand tube feeding. 
ICU denotes intensive care unit.
† Patients may have had more than one type of infection.
‡ Necrotizing pancreatitis was defined as pancreatic parenchymal necrosis or extrapancreatic necrosis.45,46 In nine patients 
(9%) in the early group and seven (7%) in the on-demand group, no CT was performed.
§  Scores on the CT severity index range from 0 to 10, with higher scores indicating more extensive pancreatic or extra-
pancreatic necrosis.
¶ New-onset organ failure was defined as organ failure that was not present at randomization. Persistent organ failure 
was defined as organ failure present on 3 or more consecutive days (>48 hours). Multiple organ failure was defined  
as failure of two or more organs on the same day.
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of the variables indicating inflammation (Fig. S3 
in the Supplementary Appendix). We did not 
evaluate gut permeability and bacterial translo-
cation on the basis of the serum intestinal fatty 
acid–binding protein level or endotoxin expo-
sure.17,50 Therefore, we cannot determine whether 
gut permeability was influenced by early feeding 
in a subset of our patients. Increased gut perme-
ability and bacterial translocation may be restrict-
ed to patients with acute pancreatitis who have 
multiple organ failure,14 a subgroup that ac-
counted for only a small fraction of the patients 
in this trial. However, a study of acute pancreati-
tis in which the rates of multiple organ failure 
and death were similar to the rates in our study 
did show an increase in gut permeability and 
endotoxin exposure in most patients with severe 
acute pancreatitis.51 
Another possibility is that tube feeding in the 
early group in our trial should have been started 
even earlier. In a trial involving a small number 
of patients at one center, it would be possible to 
start nasogastric tube feeding some hours ear-
lier by using a feeding tube that could be placed 
at the bedside. In daily practice, however, we 
believe that an earlier start of tube feeding 
would not be feasible. Starting an oral diet later 
in the on-demand group in order to increase the 
difference in timing between the two study 
groups would not be ethical because it would put 
patients at risk for malnutrition.
A third explanation for the negative result 
may be that the study was too small to detect a 
difference between the two groups. To our 
knowledge, this is the largest trial of nutrition 
in patients with acute pancreatitis that has been 
performed so far, but the wide confidence inter-
val for the primary end point may indicate that 
an even larger trial is needed.
Fourth, the widely accepted scoring systems 
Table 3. Nutrition Tolerance and Gastrointestinal Events.*
Outcome
Early 
Tube Feeding
(N = 101)
On-Demand 
Tube Feeding
(N = 104)
Risk Ratio
(95% CI) P Value
Nutrition variable
Need for nasoenteric feeding tube — no. (%) NA 32 (31) — —
Dislodging of nasoenteric feeding tube — no./total no. (%)† 38/99 (38) 14/32 (44) 0.95 (0.77–1.16) 0.68
Obstruction of nasoenteric feeding tube — no./total no. (%)† 11/99 (11)  4/32 (12) 0.97 (0.70–1.33) 0.76
Need for insertion of nasogastric tube for decompression — no. (%)‡ 19 (19) 23 (22) 0.90 (0.62–1.30) 0.61
Need for parenteral nutrition — no. (%)‡ 5 (5) 10 (10) 0.66 (0.32–1.37) 0.28
Days from admission to full tolerance of oral diet§ — 0.001
Median 9 6
Interquartile range 6–12 5–10
Gastrointestinal event — no. (%)¶
Nausea 32 (32) 37 (36) 0.91 (0.68–1.24) 0.66
Vomiting 19 (19) 26 (25) 0.82 (0.57–1.20) 0.31
Aspiration‖ 0 4 (4) — 0.12
Ileus** 10 (10) 11 (11) 0.96 (0.60–1.54) 1.00
Diarrhea 21 (21) 29 (28) 0.81 (0.57–1.17) 0.26
* NA denotes not applicable.
† Dislodging or obstruction of the nasogastric tube was noted in case-record forms by the attending physician or nurse. The denominator is 
the number of patients who had a feeding tube inserted. Two patients in the early group declined tube feeding.
‡ The need for a nasogastric tube to be inserted for decompression or the need for parenteral nutrition was indicated by the attending physician.
§ Full tolerance of an oral diet was defined as tolerance of the oral diet without receipt of any other type of nasoenteric or parenteral nutrition.
¶ Gastrointestinal events were assessed during each day of the hospital stay.
‖ Data are for suspected aspiration as noted by a physician or nurse in the case-record forms.
** Ileus was diagnosed by the attending physician and noted in the case-record forms.
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for prediction of severity in acute pancreatitis 
are only moderately accurate.52 In early-interven-
tion studies in acute pancreatitis, it is therefore 
unavoidable that mild or moderate disease will 
develop in a proportion of patients who were 
classified at presentation as having severe pan-
creatitis. Nevertheless, at randomization, approx-
imately one third of our patients had organ 
failure and two thirds had SIRS. Organ failure is 
one of the determinants of severe pancreatitis, 
and SIRS is increasingly recognized as an early 
indicator of severe pancreatitis.30,45
A feeding tube frequently causes discomfort, 
excessive gagging, or esophagitis and is often 
dislodged or becomes obstructed, which neces-
sitates the replacement of the feeding tube.53,54 
If tube feeding were restricted to patients who 
could not tolerate an oral diet, this would result 
in substantial avoidance of discomfort and costs.
In conclusion, our trial did not show the hy-
pothesized benefit of early nasoenteric tube 
feeding in patients with acute pancreatitis who 
were at high risk for complications. The observa-
tion that the clinical outcomes of early tube 
feeding were similar to those of an oral diet initi-
ated at 72 hours, with tube feeding only if re-
quired, challenges the concept of the gut mucosa–
preserving effect of early enteral feeding during 
acute pancreatitis.
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